Astellas Wins Additional U.S. Indications For Antifungal Mycamine
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma gained U.S. FDA approval of four new indications for its antifungal Mycamine (micafungin), the firm announced Jan. 22